Loading

pain

  • by NORML January 31, 2019

    Seventy-five percent of military veterans say that they would consider using either "cannabis or cannabinoid products as a treatment option," according to member survey data compiled by the group Iraq and Afghanistan Veterans of America (IAVA). The organization represents over 400,000 veterans nationwide.

    Under existing federal regulations, physicians affiliated with the Department of Veteran Affairs are forbidden from providing medical cannabis recommendations, even in jurisdictions that legally permit private practitioners to do so.

    “Federal lawmakers must stop discriminating against veterans with regard to matters of marijuana and health," said NORML Political Director Justin Strekal. "These men and women put on the uniform to defend this nation’s freedoms and it is the height of hypocrisy for the federal government to deny them rights afforded to the millions of other Americans who reside in states where access to medical cannabis is legally recognized.”

    Overall, 83 percent of respondents expressed support for legalizing medical cannabis access, and 68 percent believe that the Department of Veterans Affairs "should allow for research into cannabis as a treatment option." Proposed federal legislation to direct the agency to conduct clinical trials on the use of cannabis for PTSD and for other conditions is currently pending in the US House and Senate.

    Twenty percent of those surveyed acknowledged having previously used cannabis for medical purposes. Other studies have estimated that as many as 41 percent of veterans acknowledge having consumed cannabis for therapeutic purposes. Available data documents that cannabis is effective in the treatment of chronic pain and may potentially mitigate symptoms of post-traumatic stress, along with other conditions commonly facing veterans.

    Additional information is available from the NORML fact-sheet, "Marijuana and Veterans Issues," here.

  • by Paul Armentano, NORML Deputy Director May 8, 2018

    Medical marijuanaPatients enrolled in New York state’s medical cannabis program reduce their use of opioids and spend less money on prescription medications, according to data published online in the journal Mental Health Clinician.

    Investigators from the GPI Clinical Research in Rochester and the University of Buffalo assessed trends in patients’ medical cannabis and prescription drug use following their enrollment into the state’s marijuana access program.

    On average, subjects’ monthly analgesic prescription costs declined by 32 percent following enrollment, primarily due to a reduction in the use of opioid pills and fentanyl patches. “After three months treatment, medical cannabis improved [subjects’] quality of life, reduced pain and opioid use, and lead to cost savings,” authors concluded.

    The study’s findings are similar to those reported among enrollees in other states medical cannabis programs, including the experiences of patients in Illinois, Michigan, Minnesota, New Mexico, and elsewhere.

    The full text of the study, “Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis,” appears online here. NORML’s fact-sheet highlighting the relevant, peer-reviewed research specific to the relationship between cannabis and opioids is available online here.

  • by Paul Armentano, NORML Deputy Director March 5, 2018

    Pain reliefCannabis therapy mitigates symptoms of the chronic pain condition fibromyalgia and is associated with a reduction in the use of other prescription drugs, according to clinical data published online ahead of print in the Journal of Clinical Rheumatology. An estimated 3 to 6 million Americans are afflicted by fibromyalgia, which is often poorly controlled by standard pain medications.

    Israeli investigators assessed the safety and efficacy of inhaled cannabis in a cohort of 26 patients with fibromyalgia. They reported that medical cannabis treatment “was associated with significant favorable outcomes in every item evaluated,” such as reductions in pain and increases in energy.

    Most patients also reduced their use of conventional prescription drugs, such as opiates and benzodiazepines, during the trial period. Nearly half of the participants (46 percent) reduced their prescription drug intake by more than 50 percent during the study. Several patients were also able to return to work following the initiation of cannabis therapy.

    Researchers concluded, “Medical cannabis treatment had a significant favorable effect on patients with fibromyalgia, with few adverse effects.”

    Prior trials evaluating the use of either whole-plant cannabis or synthetic cannabinoids have similarly shown efficacy in patients with the disease. A summary of these prior studies is available here.

    The abstract of the study, “Medical cannabis for the treatment of fibromyalgia,” is online here.

  • by Paul Armentano, NORML Deputy Director March 1, 2018

    Patients routinely reduce or eliminate their use of prescription opiates following the use of medical cannabis; two recently published studies reaffirm this relationship.

    In the first study, published by the Minnesota Department of Health, investigators assessed the prescription drug use patterns of 2,245 intractable pain patients participating in the state’s medical cannabis access program. Among those patients known to be taking opiates for pain upon enrollment in the program, 63 percent “were able to reduce or eliminate opioid usage after six months.” The findings are similar to those of registered patients in other states’ medical cannabis programs, including Illinois, Michigan, and New Mexico, among others.

    In the second study, Israeli researchers assessed the safety and efficacy of cannabis in a cohort of over 1,200 cancer patients over a period of six months. Ninety-six percent of patients “reported an improvement in their condition.” Nearly half of respondents reported either decreasing or eliminating their use of opioids during the treatment period.

    A third recently published clinical trial provides insight into explaining this relationship. Investigators from the United States and Australia and assessed the efficacy of inhaled cannabis and sub-therapeutic doses of oxycodone on experimentally-induced pain in a double-blind, placebo-controlled model. Researchers assessed subjects’ pain tolerance after receiving both substances separately or in concert with one another. While neither the administration of cannabis nor oxycodone alone significantly mitigated subjects’ pain, the combined administration of both drugs did so effectively.

    Authors determined, “Both active cannabis and a low dose of oxycodone (2.5 mg) were sub-therapeutic, failing to elicit analgesia on their own; however, when administered together, pain responses … were significantly reduced, pointing to the opioid-sparing effects of cannabis.” They concluded, “Smoked cannabis combined with an ineffective analgesic dose of oxycodone produced analgesia comparable to an effective opioid analgesic dose without significantly increasing cannabis’s abuse liability.”

    The new studies add to the growing body of research finding that cannabis access is associated with reduced rates of opioid use and abuse, opioid-related hospitalizations, opioid-related traffic fatalities, opioid-related drug treatment admissions, and opioid-related overdose deaths.

    Additional information regarding the association between cannabis and opioids is available from NORML’s fact-sheet here.

  • by Paul Armentano, NORML Deputy Director February 7, 2018

    Medical marijuanaCannabis therapy is safe and effective among elderly patients diagnosed with chronic pain, according to clinical data published online ahead of print in the European Journal of Internal Medicine.

    Researchers from Hebrew University and the Ben Gurion University of Negrev in Israel assessed the use of therapeutic cannabis over a period of six months in a cohort of 1,186 patients above 65 years of age. The majority of patients enrolled in the trial suffered from pain or cancer. Under an Israeli federal program, over 32,000 citizens are licensed to utilize cannabis therapy.

    “After six months of treatment, 93.7 percent of the respondents reported improvement in their condition, and the reported pain level was reduced from a median of 8 on a scale of 0-10 to a median of 4,” researchers reported. The majority of respondents also reported “a significant improvement in [their] overall quality of life.”

    Furthermore, over 18 percent of the study’s participants “stopped using opioid analgesics or reduced their dose” – a result that led investigators to conclude, “Cannabis can decrease the use of other prescription medicines, including opioids.” Numerous prior studies, such as those compiled here, similarly show that pain patients typically mitigate or eliminate their opioid use during cannabis therapy.

    The adverse effects most commonly reported by participants were dizziness and dry-mouth.

    Authors concluded: “The older population is a large and growing part of medical cannabis users. Our study finds that the therapeutic use of cannabis is safe and efficacious in this population.”

    Read the abstract of the study, “Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly,” here.

Page 1 of 612345...Last »